Table 1.
Patient demographics and characteristics at baseline.
| Cadonilimab 15 mg/kg Q3W | Cadonilimab 10 mg/kg Q3W | Overall | |
|---|---|---|---|
| (N = 49) | (N = 20) | (N = 69) | |
| Age (year) | |||
| Median (Min, Max) | 64.0 (40, 74) | 58.5 (45, 74) | 63.5 (40, 74) |
| <65, n (%) | 29 (59.2) | 15 (75.0) | 44 (63.8) |
| >=65, n (%) | 20 (40.8) | 5 (25.0) | 25 (36.2) |
| Sex, n (%) | |||
| Male | 40 (81.6) | 18 (90.0) | 58 (84.1) |
| Female | 9 (18.4) | 2 (10.0) | 11 (15.9) |
| ECOG, n (%) | |||
| 0 | 5 (10.2) | 5 (25.0) | 10 (14.5) |
| 1 | 44 (89.8) | 15 (75.0) | 59 (85.5) |
| Smoking Status, n (%) | |||
| Never | 11 (22.4) | 4 (20.0) | 15 (21.7) |
| Former | 32 (65.3) | 14 (70.0) | 46 (66.7) |
| Current | 6 (12.2) | 2 (10.0) | 8 (11.6) |
| Clinical Stage at | |||
| Study Entry, n (%) | |||
| IIIB/IIIC | 14 (28.6) | 2 (10.0) | 16 (23.2) |
| IV | 35 (71.4) | 18 (90.0) | 53 (76.8) |
| Histological Type, n (%) | |||
| Squamous Cell | 24 (49.0) | 6 (30.0) | 30 (43.5) |
| Carcinoma | |||
| Non-squamous | 25 (51.0) | 14 (70.0) | 39 (56.5) |
| Cell Carcinoma | |||
| PD-L1 TPS, n (%) | |||
| <1% | 24 (49.0) | 2 (10.0) | 26 (37.7) |
| >=1% | 25 (51.0) | 18 (90.0) | 43 (62.3) |
| 1–49% | 22 (44.9) | 13 (65.0) | 35 (50.7) |
| >=50% | 3 (6.1) | 5 (25.0) | 8 (11.6) |
| Brain Metastasis, n (%) | 2 (4.1) | 4 (20.0) | 6 (8.7) |
| Liver Metastasis, n (%) | 3 (6.1) | 1 (5.0) | 4 (5.8) |
ECOG Eastern Cooperative Oncology Group, PD-1 programmed cell death receptor-1, PD-L1 programmed cell death ligand-1, TPS tumor proportion score, Q3W every 3 weeks.